Literature DB >> 18648767

Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.

Daniele De Luca1, Silvia Baroni, Giovanni Vento, Marco Piastra, Domenico Pietrini, Federica Romitelli, Ettore Capoluongo, Costantino Romagnoli, Giorgio Conti, Enrico Zecca.   

Abstract

PURPOSES: Secretory phospholipase A2 hydrolyzes phosphoglycerides and it has been shown to be involved in alveolar inflammation and surfactant degradation. It plays an important role in acute lung injury but it has never been studied in newborn infants. We were aimed to investigate the phospholipase A2 activity in neonatal lung injury and its relationship with ventilatory findings.
SETTING: Third level university hospital NICU.
METHODS: We measured phospholipase activity in broncho-alveolar lavage fluid of 21 neonates with hyaline membrane disease, 10 with pneumonia or sepsis and 10 controls, ventilated for extrapulmonary reasons. Fluid was obtained before surfactant administration on the first day of life and phospholipase activity was measured using an ultrasensitive enzymatic method. Before lavage, lung mechanics in pressure controlled synchronized intermittent mandatory ventilation was analyzed.
RESULTS: Phospholipase A2 was higher in babies ventilated for sepsis/pneumonia compared to hyaline membrane disease and to control babies. Phospholipase correlated negatively with dynamic compliance, positively with inspired oxygen fraction, mean airway pressure and oxygenation index. These correlations still remained significant after multivariate analysis, adjusting for possible confounding factors. Phospholipase was not correlated with blood and alveolar pH, gestational age, birth weight, blood gases, Apgar score, tidal volume, surfactant need and ventilation time.
CONCLUSIONS: These are the first data about phospholipase A2 in neonates. The enzyme plays a role in neonatal lung injury, especially in infection related respiratory failure. It is associated with lung stiffness, higher mean airway pressure and need for oxygen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18648767     DOI: 10.1007/s00134-008-1224-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  29 in total

1.  A role for phospholipase A2 in ARDS pathogenesis.

Authors:  L Touqui; L Arbibe
Journal:  Mol Med Today       Date:  1999-06

Review 2.  Interaction of secreted phospholipase A2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome.

Authors:  Lhousseine Touqui; Yong-Zheng Wu
Journal:  Acta Pharmacol Sin       Date:  2003-12       Impact factor: 6.150

3.  European consensus guidelines on the management of neonatal respiratory distress syndrome.

Authors:  David Sweet; Giulio Bevilacqua; Virgilio Carnielli; Gorm Greisen; Richard Plavka; Ola Didrik Saugstad; Umberto Simeoni; Christian P Speer; Adolf Valls-I-Soler; Henry Halliday
Journal:  J Perinat Med       Date:  2007       Impact factor: 1.901

Review 4.  The growing phospholipase A2 superfamily of signal transduction enzymes.

Authors:  E A Dennis
Journal:  Trends Biochem Sci       Date:  1997-01       Impact factor: 13.807

5.  Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Authors:  Edward Abraham; Chris Naum; Venkata Bandi; Daniel Gervich; Stephen F Lowry; Richard Wunderink; Roland M Schein; William Macias; Simona Skerjanec; Alex Dmitrienko; Nagy Farid; S Thomas Forgue; Frank Jiang
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

6.  Epithelial lining fluid free IGF-I-to-PAPP-A ratio is associated with bronchopulmonary dysplasia in preterm infants.

Authors:  Ettore Capoluongo; Franco Ameglio; Paola Lulli; Angelo Minucci; Concetta Santonocito; Paola Concolino; Enrico Di Stasio; Simona Boccacci; Valentina Vendettuoli; Giuseppe Giuratrabocchetta; Angela De Cunto; Milena Tana; Costantino Romagnoli; Cecilia Zuppi; Giovanni Vento
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-09-05       Impact factor: 4.310

7.  Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice.

Authors:  Sawako Yoshikawa; Takashige Miyahara; Susan D Reynolds; Barry R Stripp; Mircea Anghelescu; Fabien G Eyal; James C Parker
Journal:  J Appl Physiol (1985)       Date:  2004-12-17

8.  Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction.

Authors:  R Duncan Hite; Michael C Seeds; Anca M Safta; Randolph B Jacinto; Julianna I Gyves; David A Bass; B Moseley Waite
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-10-29       Impact factor: 5.464

9.  Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study.

Authors:  Enrico Zecca; Daniele De Luca; Silvia Baroni; Giovanni Vento; Eloisa Tiberi; Costantino Romagnoli
Journal:  Pediatrics       Date:  2008-01       Impact factor: 7.124

10.  Surfactant therapy in full-term neonates with severe respiratory failure.

Authors:  H Khammash; M Perlman; J Wojtulewicz; M Dunn
Journal:  Pediatrics       Date:  1993-07       Impact factor: 7.124

View more
  11 in total

1.  Technical problems with dynamic compliance evaluation in neonates and infants.

Authors:  Daniele De Luca; Marco Piastra; Giorgio Conti
Journal:  Intensive Care Med       Date:  2012-03-17       Impact factor: 17.440

2.  Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates.

Authors:  Daniele De Luca; Angelo Minucci; Domenico Tripodi; Marco Piastra; Domenico Pietrini; Cecilia Zuppi; Giorgio Conti; Virgilio P Carnielli; Ettore Capoluongo
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

3.  Continuous positive airway pressure (CPAP) vs noninvasive positive pressure ventilation (NIPPV) vs noninvasive high frequency oscillation ventilation (NHFOV) as post-extubation support in preterm neonates: protocol for an assessor-blinded, multicenter, randomized controlled trial.

Authors:  Yuan Shi; Daniele De Luca
Journal:  BMC Pediatr       Date:  2019-07-26       Impact factor: 2.125

4.  Mechanical induction of group V phospholipase A(2) causes lung inflammation and acute lung injury.

Authors:  Angelo Y Meliton; Nilda M Muñoz; Lucille N Meliton; Anna A Birukova; Alan R Leff; Konstantin G Birukov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-22       Impact factor: 5.464

5.  Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice.

Authors:  Nilda M Muñoz; Angelo Y Meliton; Lucille N Meliton; Steven M Dudek; Alan R Leff
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-03-13       Impact factor: 5.464

6.  Low-concentration ozone reacts with plasmalogen glycerophosphoethanolamine lipids in lung surfactant.

Authors:  Kelly M Wynalda; Robert C Murphy
Journal:  Chem Res Toxicol       Date:  2010-01       Impact factor: 3.739

7.  Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.

Authors:  Daniele De Luca; Ettore Capoluongo; Vincent Rigo
Journal:  BMC Pediatr       Date:  2011-11-08       Impact factor: 2.125

8.  Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes.

Authors:  Ascanio Tridente; Lucia De Martino; Daniele De Luca
Journal:  Respir Res       Date:  2019-02-06

9.  An Unsettled Promise: The Newborn Piglet Model of Neonatal Acute Respiratory Distress Syndrome (NARDS). Physiologic Data and Systematic Review.

Authors:  Dietmar Spengler; Nele Rintz; Martin F Krause
Journal:  Front Physiol       Date:  2019-10-30       Impact factor: 4.566

Review 10.  Year in review in Intensive Care Medicine, 2008: III. Paediatrics, ethics, outcome research and critical care organization, sedation, pharmacology and miscellanea.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2009-02-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.